Michael Vasconcelles, M.D.
Dr. Vasconcelles has served as a director since October 2026. Dr. Vasconcelles is a life sciences executive and hematologist-oncologist with approximately 35 years of experience in oncology research and development, medical affairs and executive leadership. Most recently, he served as Head of Research and Development at Day One Biopharmaceuticals, where he helped expand the company’s pipeline beyond OJEMDA® (tovorafenib), including through its acquisition of Mersana Therapeutics.
Prior to joining Day One, Dr. Vasconcelles served as Executive Vice President and Head of Research, Development and Medical Affairs at ImmunoGen, where he helped advance the organization into a vertically integrated biotechnology company and supported the global launch and lifecycle strategy for ELAHERE® (mirvetuximab soravtansine). He previously served as Chief Medical Officer at Flatiron Health and Unum Therapeutics and as Global Head of the Oncology Therapy Area Unit at Takeda Pharmaceuticals. Earlier in his career, he held oncology leadership roles at Genzyme and served on the faculty of Harvard Medical School and as a staff physician at Brigham and Women’s Hospital and Dana-Farber Cancer Institute.
Dr. Vasconcelles serves on the Boards of Directors of Molecular Partners AG and Kura Oncology, Inc. He received his B.A. and M.D. from Northwestern University. The Board believes that Dr. Vasconcelles’s extensive oncology development, medical and executive leadership experience qualifies him to serve as a member of our Board.